Cargando…

A multifactorial ‘Consensus Signature’ by in silico analysis to predict response to neoadjuvant anthracycline-based chemotherapy in triple-negative breast cancer

BACKGROUND: Owing to the complex processes required for anthracycline-induced cytotoxicity, a prospectively defined multifactorial Consensus Signature (ConSig) might improve prediction of anthracycline response in triple-negative breast cancer (TNBC) patients, whose only standard systemic treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Turner, Natalie, Forcato, Mattia, Nuzzo, Simona, Malorni, Luca, Bicciato, Silvio, Di Leo, Angelo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515202/ https://www.ncbi.nlm.nih.gov/pubmed/28721363 http://dx.doi.org/10.1038/npjbcancer.2015.3

Ejemplares similares

Computational methods for the integrative analysis of single-cell data
por: Forcato, Mattia, et al.
Publicado: (2020)

GDA, a web-based tool for Genomics and Drugs integrated analysis
por: Caroli, Jimmy, et al.
Publicado: (2018)

A MicroRNA Expression Signature In Taxane-anthracycline-based Neoadjuvant Chemotherapy Response
por: Zheng, Yi, et al.
Publicado: (2015)

Comparison of computational methods for Hi-C data analysis
por: Forcato, Mattia, et al.
Publicado: (2017)

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study
por: Di Cosimo, Serena, et al.
Publicado: (2019)

Immunotherapy in combination with neoadjuvant anthracycline‑free chemotherapy for triple‑negative early breast cancer: A case report
por: Zhao, Xiangwang, et al.
Publicado: (2023)

Anthracyclines versus No Anthracyclines in the Neoadjuvant Strategy for HER2+ Breast Cancer: Real-World Evidence
por: de Pinho, Inês Soares, et al.
Publicado: (2023)

Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer
por: Omar, Mohamed, et al.
Publicado: (2023)

Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen
por: Giacchetti, S, et al.
Publicado: (2014)

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy
por: Darb-Esfahani, Silvia, et al.
Publicado: (2016)

An Immune-Associated Genomic Signature Effectively Predicts Pathologic Complete Response to Neoadjuvant Paclitaxel and Anthracycline-Based Chemotherapy in Breast Cancer
por: Fu, Changfang, et al.
Publicado: (2021)

Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation
por: Dieci, Maria Vittoria, et al.
Publicado: (2022)

Transcriptional profiling of human bronchial epithelial cell BEAS-2B exposed to diesel and biomass ultrafine particles
por: Grilli, Andrea, et al.
Publicado: (2018)

ETV7 regulates breast cancer stem-like cell features by repressing IFN-response genes
por: Pezzè, Laura, et al.
Publicado: (2021)

Clinical and Pathological Response to Neoadjuvant Anthracycline Based Chemotherapy in women with breast cancer
por: Olfa, Gharbi, et al.
Publicado: (2010)

Correction: Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation
por: Dieci, Maria Vittoria, et al.
Publicado: (2022)

Hmgb3 Is Regulated by MicroRNA-206 during Muscle Regeneration
por: Maciotta, Simona, et al.
Publicado: (2012)

Dissection of Clinical and Gene Expression Signatures of Familial versus Multifactorial Chylomicronemia
por: Tremblay, Karine, et al.
Publicado: (2020)

Can Biomarker Assessment on Circulating Tumor Cells Help Direct Therapy in Metastatic Breast Cancer?
por: Turner, Natalie, et al.
Publicado: (2014)

Chromosome 17 Centromere Duplication and Responsiveness to Anthracycline-Based Neoadjuvant Chemotherapy in Breast Cancer()()
por: Tibau, Ariadna, et al.
Publicado: (2014)

Comparative hematological profiles for dose-dense vs. regular anthracycline-based neoadjuvant chemotherapy in non-metastatic breast cancer
por: Popovici, Dorel, et al.
Publicado: (2021)

ETV7 reduces inflammatory responses in breast cancer cells by repressing the TNFR1/NF-κB axis
por: Meškytė, Erna Marija, et al.
Publicado: (2023)

EphB6 Regulates TFEB-Lysosomal Pathway and Survival of Disseminated Indolent Breast Cancer Cells
por: Zangrossi, Manuela, et al.
Publicado: (2021)

Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer patients: updated follow-up data from NATT study
por: Chen, Xiaosong, et al.
Publicado: (2016)

CNA Landscape of HER2-Negative Breast Cancer in Anthracycline-Based Neoadjuvant Chemotherapy Regimens
por: Ibragimova, M. K., et al.
Publicado: (2023)

A gene signature predicts response to neoadjuvant chemotherapy in triple-negative breast cancer patients
por: Zheng, Tianzhi, et al.
Publicado: (2019)

Gene signature‐based prediction of triple‐negative breast cancer patient response to Neoadjuvant chemotherapy
por: Zhao, Yanding, et al.
Publicado: (2020)

Cardiotoxicity of anthracycline therapy: current perspectives
por: Valcovici, Mihaela, et al.
Publicado: (2016)

Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients
por: Miolo, Gianmaria, et al.
Publicado: (2014)

Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients
por: Ricciardi, Maria Rosaria, et al.
Publicado: (2018)

Perforación intestinal multifactorial /
por: Maldonado Benavides, Virginia
Publicado: (1997)

Topoisomerase 2 alpha as a predictor of response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer
por: Shehata, M, et al.
Publicado: (2010)

The Predictive Value of Serum HER2/neu for Response to Anthracycline-Based and Trastuzumab-Based Neoadjuvant Chemotherapy
por: Lee, Jung Sun, et al.
Publicado: (2012)

Metabolomics and Network Analyses Reveal Phenylalanine and Tyrosine as Signatures of Anthracycline-Induced Hepatotoxicity
por: Liu, Peipei, et al.
Publicado: (2023)

Explaining Gender Differences in Caries: A Multifactorial Approach to a Multifactorial Disease
por: Ferraro, Maria, et al.
Publicado: (2010)

Glucocorticoid receptor signalling activates YAP in breast cancer
por: Sorrentino, Giovanni, et al.
Publicado: (2017)

Cardiotoxicity of Anthracyclines
por: Cardinale, Daniela, et al.
Publicado: (2020)

Targeting nucleotide metabolism enhances the efficacy of anthracyclines and anti-metabolites in triple-negative breast cancer
por: Davison, Craig, et al.
Publicado: (2021)

HORMAD1 overexpression predicts response to anthracycline–cyclophosphamide and survival in triple‐negative breast cancers
por: El‐Botty, Rania, et al.
Publicado: (2023)

The calcineurin-NFAT pathway controls activity-dependent circadian gene expression in slow skeletal muscle
por: Dyar, Kenneth A., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_pt2h234pdktjj40e9a2c5ik9o8